ACRO, Drugmakers Seek Clearer Guidance on Multiple-Endpoint Trials

Clinical Trials Advisor
A A
Clinical research organizations and pharmaceutical companies are seeking greater clarity in an FDA draft guidance covering clinical trials with multiple endpoints.

To View This Article:

Login

Subscribe To Clinical Trials Advisor